Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in mallard ducks

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2171-2181

  Achenbach, Jenna E ^a,c   Bowen, Richard A ^b  

^a Departments of Microbiology   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; DRINKING WATER; VIRUS SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; AVIAN INFLUENZA VIRUS; CONTROLLED STUDY; DUCK; ENVIRONMENTAL EXPOSURE; FLUID INTAKE; GENETIC SELECTION; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; INFLUENZA VIRUS A H5N2; MICROBIAL POPULATION DYNAMICS; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DUCKS; ENVIRONMENTAL POLLUTANTS; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA IN BIRDS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRAL LOAD; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84876229065     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02126-12     Document Type: Article

References (58)

1. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111.
2. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
3. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765.
4. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: isolation of drugresistant H5N1 virus. Nature 437:1108.
5. de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NV, Cam BV, Qui PT, Ha DQ, Guan Y, Peiris JSM, Hien TT, Farrar J. 2005. Brief report - oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
6. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. 2007. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 13:1354-1357.
7. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
8. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. 2009. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 15:155-162.
9. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, Obert C, Seiler P, Keating R, Suzuki Y, Hiramatsu H, Govorkova EA, Webster RG. 2010. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J. Gen. Virol. 91:949-959.
10. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, George KS, Epperson S, Brammer L, Klimov AI, Bresee JS, Fry AM, Oseltamivir-Resistance Working Group. 2009. Infections with oseltamivir- resistant influenza A (H1N1) virus in the United States. JAMA 301:1034-1041.
11. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, Schweiger B, Opp M, Paget J, van de Kassteele J, Hay A, Zambon M, European Influenza Surveillance Scheme. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
12. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei IP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D'Souza H, Komadina N, Shaw R, Kelso A, Barr IG. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
13. Hauge SH, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P. 2009. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Virol. J. 6:54.
14. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. 2007. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51: 1414-1424.
15. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
16. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49:4075-4084.
17. Ives JAL, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antiviral Res. 55:307-317.
18. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. 2007. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81:12418-12426.
19. Hurt AC, Nor'e SS, McCaw JM, Fryer HR, Mosse J, McLean AR, Barr IG. 2010. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets using a competitive-mixtures model. J. Virol. 84:9427-9438.
20. Bouvier NM, Lowen AC, Palese P. 2008. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J. Virol. 82:10052-10058.
21. Accinelli C, Sacca ML, Fick J, Mencarelli M, Lindberg R, Olsen B. 2010. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 79:891-897.
22. Accinelli C, Barra Caracciolo A, Grenni P. 2007. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples. Int. J. Environ. Anal. Chem. 87:579-587.
23. Bartels P, von Tumpling W. 2008. The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. Sci. Total Environ. 405: 215-225.
24. Fick J, Lindberg RH, Tysklind M, Haemig PD, Waldenstrom J, Wallensten A, Olsen B. 2007. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS One 2:e986. doi:10.1371/journal .pone.0000986.
25. Hutchinson TH, Beesley A, Frickers PE, Readman JW, Shaw JP, Straub JO. 2009. Extending the environmental risk assessment for oseltamivir (Tamiflu) under pandemic use conditions to the coastal marine compartment. Environ. Int. 35:931-936.
26. Sacca ML, Accinelli C, Fick J, Lindberg R, Olsen B. 2009. Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere 75:28-33.
27. Singer AC, Nunn MA, Gould EA, Johnson AC. 2007. Potential risks associated with the proposed widespread use of Tamiflu. Environ. Health Persp. 115:102-106.
28. Straub JO. 2009. An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenzaand pandemic-use conditions. Ecotox. Environ. Safe. 72:1625-1634.
29. Soderstrom H, Jarhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J. 2009. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS One 4:e6064. doi:10.1371/journal.pone.0006064.
30. Ghosh GC, Nakada N, Yamashita N, Tanaka H. 2010. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ. Health Persp. 118:103-107.
31. Achenbach JE, Bowen RA. 2011. Transmission of avian influenza A viruses among species in an artificial barnyard. PLoS One 6:e17643. doi: 10.1371/journal.pone.0017643.
32. Chander Y, Jindal N, Stallknecht DE, Sreevatsan S, Goyal SM. 2010. Full-length sequencing of all nine subtypes of the neuraminidase gene of influenza A viruses using subtype specific primer sets. J. Virol. Met. 165: 116-120.
33. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146:2275-2289.
34. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739.
35. Latorra D, Campbell K, Wolter A, Hurley JM. 2003. Enhanced allelespecific PCR discrimination in SNP genotyping using 3= locked nucleic acid (LNA) primers. Hum. Mutat. 22:79-85.
36. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. 1989. Analysis of any point mutation in DNA - the amplification refractory mutation system (ARMS). Nucleic Acids Res. 17:2503-2516.
37. Renaud C, Kuypers J, Corey L. 2010. Diagnostic accuracy of an allelespecific reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant mutation in 2009 pandemic influenza A/H1N1 virus. J. Clin. Virol. 49:21-25.
38. Whitley RJ. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133.
39. Jarhult JD, Muradrasoli S, Wahlgren J, Soderstrom H, Orozovic G, Gunnarsson G, Brojer C, Latorre-Margalef N, Fick J, Grabic R, Lennerstrand J, Waldenstrom J, Lundkvist A, Olsen B. 2011. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. PLoS One 6:24742. doi:10.1371/journal.pone.0024742.
40. Gerloff NA, Kremer JR, Mossong J, Opp M, Muller CP. 2009. Genomic diversity of oseltamivir-resistant influenza virus A (H1N1), Luxembourg, 2007-08. Emerg. Infect. Dis. 15:1523-1524.
41. Kaverin NV, Gambaryan AS, Bovin NV, Rudneva IA, Shilov AA, Khodova OM, Varich NL, Sinitsin BV, Makarova NV, Kropotkina EA. 1998. Postreassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match. Virology 244:315-321.
42. Mitnaul LJ, Matrosovich MN, Castrucci MR, Tuzikov AB, Bovin NV, Kobasa D, Kawaoka Y. 2000. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J. Virol. 74:6015-6020.
43. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4:e1000103. doi:10.1371/journal.ppat.1000103.
44. Wagner R, Matrosovich M, Klenk HD. 2002. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12:159-166.
45. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. 1996. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70:1818-1827.
46. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, Hart GJ, Bethell RC, Penn CR. 1996. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino- Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40:40-46.
47. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE, Laver WG. 1995. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214:642-646.
48. McCullough C, Wang M, Rong L, Caffrey M. 2012. Characterization of influenza hemagglutinin interactions with receptor by NMR. PLoS One 7:e33958. doi:10.1371/journal.pone.0033958.
49. Colman PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44.
50. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43:1555-1561.
51. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760-764.
52. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu XY, Klimov AI, Gubareva LV. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 54:1834-1841.
53. Levine M, Sheu TG, Gubareva LV, Mishin VP. 2011. Detection of hemagglutinin variants of the pandemic influenzaA(H1N1) 2009 virus by pyrosequencing. J. Clin. Microbiol. 49:1307-1312.
54. Chidlow GR, Harnett GB, Williams SH, Tempone SS, Speers DJ, Hurt AC, Deng YM, Smith DW. 2010. The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses using a real-time RT-PCR assay. J. Virol. Methods 169:47-51.
55. Liu CM, Driebe EM, Schupp J, Kelley E, Nguyen JT, McSharry JJ, Weng QM, Engelthaler DM, Keim PS. 2010. Rapid quantification of singlenucleotide mutations in mixed influenza A viral populations using allelespecific mixture analysis. J. Virol. Methods 163:109-115.
56. van der Vries E, Jonges M, Herfst S, Maaskant J, Van der Linden A, Guldemeester J, Aron GI, Bestebroer TM, Koopmans M, Meijer A, Fouchier RAM, Osterhaus ADME, Boucher CA, Schutten M. 2010. Evaluation of a rapid molecular algorithm for detection of pandemic influenzaA (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J. Clin. Virol. 47:34-37.
57. Brennan BJ, Davies B, Cirrincione-Dall G, Morcos PN, Beryozkina A, Chappey C, Baldo PA, Lennon-Chrimes S, Rayner CR. 2012. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers. Antimicrob. Agents Chemother. 56:4729-4737.
58. He G, Massarella J. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-484.